1. Home
  2. EME vs BIIB Comparison

EME vs BIIB Comparison

Compare EME & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EMCOR Group Inc.

EME

EMCOR Group Inc.

N/A

Current Price

$607.37

Market Cap

28.3B

Sector

Industrials

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

N/A

Current Price

$250.64

Market Cap

34.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EME
BIIB
Founded
1987
1978
Country
United States
United States
Employees
25000
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3B
34.5B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
EME
BIIB
Price
$607.37
$250.64
Analyst Decision
Buy
Buy
Analyst Count
13
36
Target Price
★ $875.60
$268.26
AVG Volume (30 Days)
485.8K
★ 1.1M
Earning Date
10-29-2026
10-28-2026
Dividend Yield
★ 0.25%
N/A
EPS Growth
★ 30.99
N/A
EPS
★ 24.93
2.66
Revenue
★ $16,986,422,000.00
$9,890,600,000.00
Revenue This Year
$23.11
$7.00
Revenue Next Year
$13.99
$1.82
P/E Ratio
★ $25.52
$92.96
Revenue Growth
★ 16.62
2.22
52 Week Low
$579.48
$160.36
52 Week High
$951.96
$261.00

Technical Indicators

Market Signals
Indicator
EME
BIIB
Relative Strength Index (RSI) 35.23 54.94
Support Level $579.48 $240.00
Resistance Level $858.99 $259.89
Average True Range (ATR) 26.58 7.20
MACD 0.13 -1.24
Stochastic Oscillator 19.48 50.24

Price Performance

Historical Comparison
EME
BIIB

About EME EMCOR Group Inc.

Emcor designs, installs, and maintains a host of electrical and mechanical systems, including power, communications, HVAC, and plumbing, for a variety of customers, including data centers, semiconductor fabs, healthcare, and water treatment. It operates through more than 100 subsidiaries and actively pursues bolt-on acquisitions to expand into additional geographies in the USA.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: